Psychiatry Research: Neuroimaging
Volume 148, Issue 2 , Pages 121-132 , 1 December 2006

Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment

  • Robert K. McClure

      Affiliations

    • University of North Carolina at Chapel Hill, Department of Psychiatry, Chapel Hill, NC, United States
    • Corresponding Author InformationCorresponding author. UNC Department of Psychiatry, CB 7160, Room 247, Wing C, Chapel Hill, NC 27510-7160, United States. Tel.: +1 919 843 6629; fax: +1 919 966 4180.
    • ,
  • Ingrid Phillips

      Affiliations

    • Clinical Brain Disorders Branch, NIMH, Bethesda, MD, United States
    • ,
  • Roukan Jazayerli

      Affiliations

    • George Washington University, Department of Psychiatry, Washington DC, United States
    • ,
  • Allan Barnett

      Affiliations

    • Clinical Brain Disorders Branch, NIMH, Bethesda, MD, United States
    • ,
  • Richard Coppola

      Affiliations

    • Clinical Brain Disorders Branch, NIMH, Bethesda, MD, United States
    • ,
  • Daniel R. Weinberger

      Affiliations

    • Clinical Brain Disorders Branch, NIMH, Bethesda, MD, United States

Received 3 April 2006 ,Revised 16 April 2006 ,Accepted 28 April 2006.

References 

  1. Ananth H, Popescu I, Crightly HD, Good CD, Frackowiak RSJ, Dolan RJD. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized VBM. American Journal of Psychiatry. 2002;159:1497–1505
  2. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2002;27:143–151
  3. Arango C, Breier A, McMahon R, Carpenter W, Buchanan R. The relationship of clozapine and haloperidol treatment responses to prefrontal, hippocampal, and caudate brain volumes. American Journal of Psychiatry. 2003;160:1421–1427
  4. Bartko JJ. The intraclass correlation coefficient as a measure of reliability. Psychological Reports. 1966;19:3–11
  5. Bernard V, Le Moine BB. Striatal neurons express increased level of D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. Neuroscience. 1991;45:117–126
  6. Bowers MB. Homovanillic acid in caudate and pre-frontal cortex following neuroleptics. European Journal of Pharmacology. 1984;99:103–105
  7. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biological Psychiatry. 1987;22:479–494
  8. Cahn W, Hulshoff P, Lems E, van Haren NEM, Schnack HG, van der Linden JA, et al. Brain volume changes in first-episode schizophrenia. A 1-year follow-up study. Archives General Psychiatry. 2002;59:1002–1010
  9. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry. 1994;151:1430–1436
  10. Chakos MH, Lieberman JA, Alvir J, Bilder RM, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 1995;345(8947):456–457
  11. Chakos MH, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga CA. Striatal enlargement in rats chronically treated with neuroleptic. Biological Psychiatry. 1998;44:675–684
  12. Chakos MH, Schobel S, Gu H, Gerig G, Bradford D, Lieberman J. Association of duration of illness and treatment effects on hippocampal volume in male schizophrenic patients. Society for Biological Psychiatry. 2002;51:162S
  13. Chiodo LA, Bunney BS. Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences. Journal of Neuroscience. 1987;7:629–633
  14. Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Research. Neuroimaging. 2004;130:71–78
  15. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreason NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. American Journal of Psychiatry. 1999;156:1200–1204
  16. Davis KL, Buchsbaum MS, Shihabuddin L, Speigel-Cohen J, Metzger MF, Keefe RS, et al. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry. 1998;43:783–793
  17. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Experimental Neurology. 1995;133:175–188
  18. DeLisi LE, Stritzke P, Riordan H, Holan V, Boccio A, Kushner M, et al. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. Biological Psychiatry. 1992;31:241–254
  19. DeLisi LE, Tew W, Xie S, Hoff AL, Sakuma M, Kushner M, et al. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biological Psychiatry. 1995;38:349–360
  20. DeLisi L, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Research. Neuroimaging. 1997;74:129–140
  21. Eastwood SL, Burnet PWJ, Harrison PJ. Striatal synaptophysin expression and haloperidol-induced synaptic plasticity. NeuroReport. 1994;5:677–680
  22. First MB. User's Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: SCID-II. Washington, DC: American Psychiatric Press; 1997;
  23. Garver DL, Nair TR, Christensen JD, Holcomb JA, Kingsbury SL. Brain and ventricular instability during psychotic episodes of the schizophrenias. Schizophrenia Research. 2000;44:11–23
  24. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biological Psychiatry. 2005;58:62–66
  25. Gerig, G., Muller, K.E., Kistner, E.O., Chi, Y.Y., McClure, R.K., Styner, M., Lieberman, J.A., submitted for publication. Regionally specific changes in hippocampal shape relate to age and antipsychotic type in schizophrenia.
  26. Gilbert AR, Moore GJ, Keshavan MS, Paulson AD, Narula V, MacMaster FP, et al. Decrease in thalamic volumes of pediatric patients with obsessive–compulsive disorder who are taking paroxetine. Archives of General Psychiatry. 2000;57:449–456
  27. Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A voxel-based morphometric study of ageing in 465 normal human adult brains. NeuroImage. 2001;14:21–36
  28. Good CD, Cahil RI, Fox NC, Ashburner J, Friston KJ, Chan D, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. NeuroImage. 2002;17:29–46
  29. Gotgay N, Sporn A, Clasen LS, Nugent TF, Greenstein D, Nicolson R, et al. Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood onset atypical psychosis. Archives of General Psychiatry. 2004;61:17–22
  30. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Archives of General Psychiatry. 1998;55:145–152
  31. Gur RC, Turetsky BI, Bilker W, Gur RE. Volumetric MRI measures in relation to clinical status in schizophrenia. Philadelphia, PA: Presented at the Annual Meeting of the Society for Biological Psychiatry; 2002;
  32. Hirayasu YEA. Progressive change in posterior superior temporal gyrus in schizophrenia. Biological Psychiatry. 1999;45:117S
  33. Hulshoff H, Schnack HG, Mandl RCW, van Haren NEM, Koning H, Collins L, et al. Focal gray matter density changes in schizophrenia. Archives of Gen Psychiatry. 2001;58:1118–1125
  34. Hyman SE, Nestler EJ. The Molecular Foundations of Psychiatry. Washington, DC: American Psychiatric Press; 1993;
  35. Jacobsen LK, Giedd JN, Castellanos FX, Vaituzis AC, Hamburger SD, Kumra S, et al. Progressive reduction of temporal lobe structures in childhood-onset schizophrenia. American Journal of Psychiatry. 1998;155:678–685
  36. Jarskog LF, Gilmore JH, Charles HC, Lieberman JA. Expanding the concept of neurodegeneration in schizophrenia. 2002;(unpublished)
  37. Jarskog L, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ration without caspase-3 activation. American Journal of Psychiatry. 2004;161:109–115
  38. Job DE, Whalley HC, McConnell S, Glabus MF, Johnstone EC, Lawrie SM. Structural gray matter differences between first-episode schizophrenics and normal controls using voxel-based morphometry. NeuroImage. 2002;17:880–889
  39. Kay SR, Opler FA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  40. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet. 1994;344:1434
  41. Kubicki M, Shenton ME, Salisbury DF, Hirayasu KK, Kikinis R, Jolesz FA, et al. Voxel-based morphometric analysis of gray matter in first-episode schizophrenia. NeuroImage. 2002;17:1711–1719
  42. Lieberman J. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry. 1999;46:729–739
  43. Lieberman J. Antipsychotic treatment effects on progression of brain pathomorphology in first-episode schizophrenia. In: Proceedings, American College of Neuropsychopharmacology 41st Annual Meeting, San Juan, Puerto Rico. 2002;p. 24
  44. Lieberman JA, Chakos MA, Wu H, Alvir J, Hoffman E, Robinson D, et al. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry. 2001;49:487–499
  45. Lieberman JA, Tollefson GD, Charles CC, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 2005;62:361–370
  46. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men. Archives of General Psychiatry. 2001;58:148–157
  47. McCarley RW, Shenton ME, Kasai K, Hirayasu Y, Salisbury DF. In: Progression of gray matter loss after first episode in schizophrenia but not in bipolar psychosis. Philadelphia PA: Proceedings, Society for Biological Psychiatry; 2002;p. 11S
  48. Meshul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Research and Molecular Brain Research. 1987;489:338–346
  49. Moore GJ, Bebchuck JM, Wilds IB, Chen G, Manji HK. Pharmacological increase in human brain gray matter. Lancet. 2000;356:1241
  50. Nair TR, Christensen JD, Kingsbury SJ, Kumar NG, Terry WM, Garver DL. Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Research. Neuromaging. 1997;74:141–150
  51. Nopoulos P, Ho BC, Pressler M, McCormick L, Andreason NC. Longitudinal assessment of the effects of neuroleptic medications on global cerebral measures in subjects with schizophrenia. In: Presented at the 20th International Conference on Schizophrenia Research, Savannah, GA. 2005;
  52. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2002;361:281–288
  53. Rapoport JL, Giedd J, Kumra S, Jacobsen L, Smith A, Lee P, et al. Childhood-onset: progressive ventricular change during adolescence. Archives of General Psychiatry. 1997;54:897–903
  54. Rapoport J, Giedd JN, Blumenthal J, Hamburger S, Jeffries N, Fernandez T, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. Archives of General Psychiatry. 1999;56:649–654
  55. Scheepers F, Gispen de Wied CC, Hulshoff HE, et al. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with neuroleptics. Neuropsychopharmacology. 2001;24:47–54
  56. Schweitzer JW, Schwartz R, Friedhoff AJ. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol. Research in Community Chemistry, Pathology and Pharmacology. 1982;38:21–30
  57. Shihabuddin L, Buchsbaum MS, Hazlett EA, Haznedar MM, Harvey PD, Newman A, et al. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Archives of General Psychiatry. 1998;55:235–243
  58. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology. 2000;152:174–180
  59. Sowell E, Levitt J, Thompson PM, Holmes CJ, Blanton RE, Kornsand DS, et al. Brain abnormalities in early-onset schizophrenia spectrum disorder observed with statistical parametric mapping of structural magnetic resonance images. American Journal of Psychiatry. 2000;157:1475–1484
  60. Sporn AS, Greenstein DK, Gogtay N, Jeffries NO, Lenane M, Gochman P, et al. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. American Journal of Psychiatry. 2003;160:2181–2189
  61. Thompson P, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:11650–11655
  62. Tisserand DJ, Pruessner JC, Sanz A, van Boxtel MPJ, Evans AC, Jolles J, et al. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. NeuroImage. 2002;657–669
  63. Vetsa, S.K., Styner, S., Pizer, S.M., McClure, R.K., Lieberman, J.A., Gerig, G., submitted for publication. Differences in caudate size and shape using template-free non-parametric tests associated with antipsychotic treatment in schizophrenia.
  64. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?. Archives of General Psychiatry. 2002;59:553–558
  65. Wilke M, Kaufmann C, Grabner A, Putz B, Wettter TC, Auer DP. Gray matter-changes and correlates of disease severity in schizophrenia: a statistical parametric mapping study. NeuroImage. 2001;13:814–824
  66. Wright IC, Ellison ZR, Sharma T, Friston KJ, Murray RM, Macguire PK. Mapping of grey matter changes in schizophrenia. Schizophrenia Research. 1999;35:1–19

PII: S0925-4927(06)00087-4

doi: 10.1016/j.pscychresns.2006.04.008

Psychiatry Research: Neuroimaging
Volume 148, Issue 2 , Pages 121-132 , 1 December 2006

Article Tools

* Image Usage & Resolution